- Home
- MYGN vs MLTX Comparison
MYGN vs MLTX Comparison
Compare MYGN & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- MLTX
- Stock Information
- Founded
- MYGN 1991
- MLTX 2021
- Country
- MYGN United States
- MLTX Switzerland
- Employees
- MYGN N/A
- MLTX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- MLTX Health Care
- Exchange
- MYGN Nasdaq
- MLTX Nasdaq
- Market Cap
- MYGN 642.0M
- MLTX 595.6M
- IPO Year
- MYGN 1995
- MLTX N/A
- Fundamental
- Price
- MYGN $8.33
- MLTX $9.82
- Analyst Decision
- MYGN Hold
- MLTX Buy
- Analyst Count
- MYGN 13
- MLTX 9
- Target Price
- MYGN $13.50
- MLTX $37.63
- AVG Volume (30 Days)
- MYGN 959.5K
- MLTX 12.2M
- Earning Date
- MYGN 11-04-2025
- MLTX 11-07-2025
- Dividend Yield
- MYGN N/A
- MLTX N/A
- EPS Growth
- MYGN N/A
- MLTX N/A
- EPS
- MYGN N/A
- MLTX N/A
- Revenue
- MYGN $832,900,000.00
- MLTX N/A
- Revenue This Year
- MYGN $0.06
- MLTX N/A
- Revenue Next Year
- MYGN $5.68
- MLTX N/A
- P/E Ratio
- MYGN N/A
- MLTX N/A
- Revenue Growth
- MYGN 3.83
- MLTX N/A
- 52 Week Low
- MYGN $3.76
- MLTX $5.95
- 52 Week High
- MYGN $22.92
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- MYGN 64.16
- MLTX 27.40
- Support Level
- MYGN $7.68
- MLTX $8.92
- Resistance Level
- MYGN $8.25
- MLTX $9.47
- Average True Range (ATR)
- MYGN 0.38
- MLTX 0.62
- MACD
- MYGN -0.01
- MLTX 1.54
- Stochastic Oscillator
- MYGN 78.80
- MLTX 47.44
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.